Ferucarbotran-enhanced T2-weighted magnetic resonance imaging: differentiation of hepatic cavernous hemangiomas from malignant solid lesions.

Abdominal imaging

PubMedID: 18546032

Cho ES, Yu JS, Ahn JH, Park MS, Kim JH, Chung JJ, Kim KW. Ferucarbotran-enhanced T2-weighted magnetic resonance imaging: differentiation of hepatic cavernous hemangiomas from malignant solid lesions. Abdom Imaging. 2009;34(4):494-501.
BACKGROUND
To demonstrate the characteristic feature of hepatic cavernous hemangiomas on ferucarbotran-enhanced T2-weighted MR imaging as a new diagnostic finding.

METHODS
In 201 hepatic lesions (61 hemangiomas, 61 cysts, 41 hepatocellular carcinomas, 31 metastatic carcinomas, and 7 cholangiocarcinomas), lesion-to-liver contrast on ferucarbotran-enhanced T2-weighted images was qualitatively compared with pre-contrast images by three independent readers using a four-grade scale (group 1, marked increase; group 2, mild increase; group 3, no change; group 4, decrease). The change in the contrast-to-noise ratio (CNR) for each lesion was quantitatively measured.

RESULTS
Only hemangiomas showed a significant decrease in CNR; 10% and 90% of the hemangiomas were categorized as group 3 and 4 lesions, respectively. Besides the hemangiomas, there was no other lesion categorized into group 4 except for one cyst. When group 4 lesions were considered hemangiomas, the accuracy of identification was 96.4%.

CONCLUSION
Hemangiomas show a significant decrease in lesion-to-liver contrast on T2-weighted images after ferucarbotran injection, which might be another typical diagnostic imaging finding of hemangiomas distinguished from solid malignant lesions.